In CRC, DHTS can enhance the cytotoxicity of doxorubicin and irinotecan in P-gp overexpressing SW620 Ad300 colon cancer cells by reducing P-gp mRNA and protein levels, and by inhibiting P-gp ATPase activity [32]. The gene discussed is PGP; the disease is malignant colon neoplasm.